World Bispecific Antibody Summit, September 27–28, 2011, Boston, MA

Figures & data

Table 1 Bispecific antibodies in clinical study sponsored by commercial firms

Company	INN or code name	Targets	Clinical status*
Sanofi	SAR156597	IL4 x IL13	Phase 1
Affimed	AFM13	CD30 x CD16A	Phase 1
Trion	FBT-A05, Bi20	CD20 x CD3	Phase 1
Micromet	MT110	EpCAM x CD3	Phase 1
Micromet	MT111, MEDI 565	CEA x CD3	Phase 1
Immunocore	IMCgp100	gp100 x CD3	Phase 1
Immunomedics	TF2	CEA x IMP288 hapten	Phase 1
Genentech	MEHD-7945A	EGFR x HER3; dual IgG1	Phase 1
Merrimack	MM-111	HER2 x HER3	Phase 1
Pfizer	CVX-241	Ang2 x VEGF; dual IgG1	Phase 1
Ablynx	Ozoralizumab, ATN103	TNF x albumin	Phase 2
Micromet	Blinatumomab, MT103	CD19 x CD3	Phase 2

* Most advanced phase of clinical study listed on company web page or clinicaltrials.gov as of September 2011.